Institute for Clinical & Economic Review Publishes Evidence Report on Tirzepatide for Type 2 Diabetes
January 07, 2022
January 07, 2022
BOSTON, Massachusetts, Jan. 7 (TNSRep) -- The Institute for Clinical and Economic Review issued the following news release on Jan. 6, 2022:
* * *
- Tirzepatide has a novel dual GIP and GLP-1 receptor agonist mechanism of action and is seen as an add-on type 2 diabetes therapy; tirzepatide would achieve common thresholds for cost-effectiveness if priced between $5,500 - $5,700 per year --
- At the January 20 virtual meeting, ICER's independent appraisal . . .
* * *
- Tirzepatide has a novel dual GIP and GLP-1 receptor agonist mechanism of action and is seen as an add-on type 2 diabetes therapy; tirzepatide would achieve common thresholds for cost-effectiveness if priced between $5,500 - $5,700 per year --
- At the January 20 virtual meeting, ICER's independent appraisal . . .